|
|||||
|
|
Survival in Norwegian BRCA1 mutation carriers with breast cancer |
|
| Authors: | Anne Irene Hagen Steinar Tretli Lovise Mæhle Jaran Apold Nina Vedå Pål Møller |
| Affiliation: | 1. MRC Clinical Sciences Centre, Imperial College, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK 2. Department of Histopathology, University College London, Rockefeller Building, University Street, London, WC1E 6JJ, UK 3. North West Thames Regional Genetics Service, Northwick Park & St Mark's Hospital, Watford Road, Harrow, London, HA1 3UJ, UK 4. Colon Cancer Genetics Group, University of Edinburgh Cancer Research Centre and MRC Human Genetics Unit, Western General Hospital, Edinburgh, EH4 2XU, UK 5. Institute of Medical Genetics, Cardiff University, School of Medicine, Heath Park, Cardiff, UK 6. School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, NR4 7TJ, UK 7. Human Genetics, Department of Pathology, Ninewells Hospital and Medical School, Dundee, UK 8. Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK 9. The Institute of Cancer Research, 15 Cotswold Rd, Sutton, Surrey, SM2 5NG, UK |
| Abstract: | Several studies of survival in women with BRCA1 mutations have shown either reduced survival or no difference compared to controls. Programmes for early detection and treatment of inherited breast cancer, have failed to demonstrate a significant improvement in survival in BRCA1 mutation carriers.One hundred and sixty-seven women with disease-associated germline BRCA1 mutations and breast cancer from 1980 to 2001 were identified. Tumour characteristics, treatment given and survival were recorded. A control group comprising three hundred and four women matched for age, time of diagnosis and stage were used to compare survival.BRCA1 mutation carriers were found to have a poorer prognosis, which could be explained by neither the mode of surgical treatment nor the use of adjuvant chemotherapy. BRCA1 mutation carriers with node negative breast cancer had worse overall survival than controls.Our findings confirm the serious prognosis of BRCA1-associated breast cancer even when diagnosed at an early stage, and that type of treatment does not influence prognosis. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |